Ruthenium photosensitizer anchored gold nanorods for synergistic photodynamic and photothermal therapy. Issue 17 (19th April 2022)

• Record Type: Journal Article
• Authors: Shi, Hongdong; Lin, Simin; Wang, Yi; Lou, Jingxue; Hu, Yatao; Chen, Yuyu; Zhang, Qianling
• Is Part Of: Dalton transactions. Volume 51:Issue 17(2022)
• Page Start: 6846
• Page End: 6854
• Publication Date: 2022-04-19
• Subjects: Chemistry, Inorganic -- Periodicals; Chemistry, Physical and theoretical -- Periodicals; Chemistry, Inorganic -- Periodicals; 546.05
• DOI: 10.1039/d2dt00365a
• Languages: English
• ISSNs: 1477-9226

Abstract

Abstract : A nanodrug with ruthenium photosensitizers anchored in the nanocarrier of human serum albumin coated gold nanorods was developed for synergistic photodynamic and photothermal therapy. Abstract : Ruthenium polypyridyl complexes have been widely used as bioprobes and photosensitizers. However, several disadvantages including slow cellular uptake, nonspecific binding with biomolecules and toxicity limit their applications. In this study, a nanocarrier of human serum albumin coated gold nanorods was developed to deliver a ruthenium photosensitizer for PDT/PTT combination therapy. The HSA coating endowed the nanodrug with high biocompatibility and stability under physiological conditions. Ru-GNR-HSANPs generate 1 O2 and hydroxyl radicals to kill cancer cells under blue light irradiation, and exhibit excellent photothermal anticancer effects under 808 nm light irradiation. Significant synergistic anticancer effects were achieved by combined PDT/PTT therapy. Importantly, Ru-GNR-HSANPs can have the synergistic PDT/PTT functions with no need of drug release from the carrier.